Browsing by Author "Nai Ming Lai"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- PublicationAntimicrobial dressings for the prevention of catheter-related infections in newborn infants with central venous catheters(2016)
;Nai Ming Lai ;Jacqueline E Taylor ;Kenneth Tan ;Yao Mun Choo ;Azanna Ahmad KamarNor Asiah MuhamadBackground: Central venous catheters (CVCs) provide secured venous access in neonates. Antimicrobial dressings applied over the CVC sites have been proposed to reduce catheter-related blood stream infection (CRBSI) by decreasing colonisation. However, there may be concerns on the local and systemic adverse effects of these dressings in neonates. - PublicationAutologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients(John Wiley & Sons, Ltd., 2018)
;S Fadilah Abdul Wahid ;Nor Azimah Ismail ;Wan Fariza Wan Jamaludin ;Nor Asiah Muhamad ;Muhammad Khairul Azaham Abdul Hamid ;Hanafiah HarunarashidNai Ming LaiBackground: Revascularisation is the gold standard therapy for patients with critical limb ischaemia (CLI). In over 30% of patients who are not suitable for or have failed previous revascularisation therapy (the 'no-option' CLI patients), limb amputation is eventually unavoidable. Preliminary studies have reported encouraging outcomes with autologous cell-based therapy for the treatment of CLI in these 'no-option' patients. However, studies comparing the angiogenic potency and clinical e'ects of autologous cells derived from di'erent sources have yielded limited data. Data regarding cell doses and routes of administration are also limited. Objectives: To compare the e'icacy and safety of autologous cells derived from di'erent sources, prepared using di'erent protocols, administered at di'erent doses, and delivered via di'erent routes for the treatment of 'no-option' CLI patients. Search methods: The Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINEOvid, EmbaseOvid,the Cumulative Index toNursing and AlliedHealth Literature (CINAHL),the Allied and Complementary Medicine Database (AMED), and trials registries (16 May 2018). Review authors searched PubMed until February 2017. Selection criteria: We included randomised controlled trials (RCTs) involving 'no-option' CLI patients comparing a particular source orregimen of autologous cell-based therapy against another source or regimen of autologous cell-based therapy. Data collection and analysis: Three review authors independently assessed the eligibility and methodological quality ofthe trials.We extracted outcome data from each trial and pooled them for meta-analysis. We calculated e'ect estimates using a risk ratio (RR) with 95% confidence interval (CI), or a mean di'erence (MD) with 95% CI. - PublicationEfficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis(2018)
;Fadilah S. Abdul Wahid ;Nor Azimah Ismail ;Wan Fariza Wan Jamaludin ;Nor Asiah Muhamad ;Mohamad Azim Mohamad IdrisNai Ming LaiBackground: Revascularisation therapy is the current gold standard of care for critical limb ischemia (CLI), although a significant proportion of patients with CLI either are not fit for or do not respond well to this procedure. Recently, novel angiogenic therapies such as the use of autologous cellbased therapy (CBT) have been examined, but the results of individual trials were inconsistent. Objective: To pool all published studies that compared the safety and efficacy of autologous CBT derived from different sources and phenotypes with non cell-based therapy (NCT) in CLI patients. Methods: We searched Medline, Embase, Cochrane Library and ClinicalTrials.gov from 1974-2017. Sixteen randomised clinical trials (RCTs) involving 775 patients receiving the following interventions: mobilised peripheral blood stem cells(m-PBSC), bone marrow mononuclear cells(BM-MNC), bone marrow mesenchymal stem cells(BM-MSC), cultured BM-MNC(Ixmyelocel-T), cultured PB cells(VesCell) and CD34+ cells were included in the meta-analysis. Results: High-quality evidence (QoE) showed similar all-cause mortality rates between CBT and NCT. AR reduction by approximately 60% were observed in patients receiving CBT compared to NCT (moderate QoE). CBT patients experienced improvement in ulcer healing, ABI, TcO2, pain free walking capacity and collateral vessel formation (moderate QoE). Low-to-moderate QoE showed that compared to NCT, intramuscular BM-MNC and m-PBSC may reduce amputation rate, rest pain, and improve ulcer healing and ankle-brachial pressure index, while intramuscular BM-MSC appeared to improve rest pain, ulcer healing and pain-free walking distance but not AR. Efficacy of other types of CBT could not be confirmed due to limited data. Cell harvesting and implantation appeared safe and well-tolerated with similar rates of adverse-events between groups. Conclusion: Implantation of autologous CBT may be an effective therapeutic strategy for no-option CLI patients. BM-MNC and m-PSBC appear more effective than NCT in improving AR and other limb perfusion parameters. BM-MSC may be beneficial in improving perfusion parameters but not AR, however, this observation needs to be confirmed in a larger population of patients. Generally, treatment using various sources and phenotypes of cell products appeared safe and well tolerated. Large-size RCTs with long follow-up are warranted to determine the superiority and durability of angiogenic potential of a particular CBT and the optimal treatment regimen for CLI. - PublicationEvidence mapping of interactions on concomitant use of Chinese medicine and platinum-based chemotherapy: a scoping review protocol(Elsevier, 2020)
;Ai Ch’i Liew ;Si Yan Chan ;Ren Jye Lim ;Wan Najbah Nik Nabil ;Shi Min HooNai Ming LaiBackground: The utilization of Chinese herbal medicine (CHM) has gained popularity and acceptance worldwide. Increasing use of CHM either as a stand-alone or an adjunctive treatmentfor cancers has given rise to increasing concern on potential herbal-drug reactions. Possible combinatory effects are important to be explored in evaluating the rationality of integrating CHM and chemotherapy in clinical practice. This study aims to update the current knowledge on herbal-drug interactions (HDI) of the commonly used platinum-based chemotherapy (PtC) in cancer patients. Methods: Systemic searches will perform on online databases (English and Chinese) to identify papers from inception until December 2019 for inclusion into the review. The search strategy will be following PRISMA Scoping Reviews Checklist as a quality assurance step. All records retrieved will be screened by 2 independent reviewers. The preclinical studies and clinical studies that involve in assessing the concurrent use of CHM and PtC will be considered. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses will be used as scoping review framework. Discussion: This scoping review will explore the compatibility or combination rule of CHM-PtC and assist in understanding HDI in CHM-PtC co-treatment. Identification of active properties in CHM’s HDI and understanding pharmacokinetics and pharmacodynamic of the CHM alone or as co-treatment are essential for patients’ safety profile. It will provide a new insight for future practice in cancer treatment. Study registration: This protocol has been registered in the Research Register (https://www. researchregistry.com/) with an unique registration number: reviewregistry790 - PublicationSeroprevalence of Hepatitis B Among Healthcare Workers in Asia and Africa and Its Association With Their Knowledge and Awareness: A Systematic Review and Meta-Analysis(2022)
;Nur Hasnah Maamor ;Nor Asiah Muhamad ;Nor Soleha Mohd Dali ;Mohd Hatta Abdul Mutalip ;Fatin Norhasny Leman ;Tahir Aris ;Nai Ming LaiMuhammad Radzi Abu HassanThe hepatitis B virus (HBV) is a blood-borne virus that can be transmitted by percutaneous and mucocutaneous contact with infected bodily fluid. Healthcare workers (HCWs) are more exposed to HBV infection. They must have a thorough understanding of HBV infection since they can contract and spread the virus. In this study, we systematically reviewed all published evidence on the seroprevalence of Hepatitis B virus (HBV) infection among HCWs. and synthesize evidence on the association between knowledge and awareness with HBV infection. MethodsWe searched PubMed, EMBASE, Cochrane Library and Scopus for studies reporting on HBV seroprevalence from January 1997 to September 2021 among healthcare workers. We used random-effects meta-analyses to estimate the pool prevalence of HBV infection.ResultsWe identified 25 studies that met our inclusion criteria, with data on 10,043 adults from 11 countries and two regions: Africa and Asia. The overall seroprevalence of HBV was 5.0% (95% confidence interval [CI] 3.6%), with Africa reporting higher estimates (5.0%, 95% CI 3.7%) than Asia population (4.0%, 95% CI 1.9%). The highest pooled prevalence estimate in African countries came from studies published in the Cameroon region (8.0%, 95% CI 5–10%) while the lowest came from Ethiopia (4.0%, 95% CI 2.6%). The overall seroprevalence estimates in the African population were significantly higher than those in the Asian group. Studies in Africa found that the average knowledge and seroprevalence were 1.4% and 11.0%, respectively where, eight studies (53.3%) reported good knowledge and seven studies (46.7%) reported average knowledge. In Asia, two studies (40.0%) reported good knowledge, one study (20.0%) reporting average knowledge, and two studies (40.0%) reporting poor knowledge. African studies demonstrated good knowledge despite the fact that their HBV infection rate was higher than 6.7%.ConclusionAfrica and Asia have the highest seroprevalence of HBV infection. Improving the comparability of epidemiological and clinical studies constitutes an important step forward. More high-quality data is needed to improve the precision of burden estimates.Systematic Review RegistrationPROSPERO CRD42021279905.